StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Stock analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Monday. The firm set a “hold” rating on the stock.

Several other equities research analysts have also recently issued reports on ONCT. Northland Capmk cut shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Finally, Northland Securities reiterated a “market perform” rating and issued a $2.00 price objective on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, Oncternal Therapeutics currently has an average rating of “Hold” and an average price target of $10.00.

Oncternal Therapeutics Price Performance

Shares of NASDAQ:ONCT opened at $0.53 on Monday. Oncternal Therapeutics has a 1 year low of $0.53 and a 1 year high of $13.14. The firm has a market capitalization of $1.56 million, a PE ratio of -0.05 and a beta of 1.18. The business’s 50 day moving average price is $0.83 and its 200-day moving average price is $3.02.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.